APA (7th ed.) Citation

Epperla, N., Nastoupil, L. J., Feinberg, B., Galvin, J., Pathak, P., Amoloja, T., . . . Saverno, K. Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. BMC.

Chicago Style (17th ed.) Citation

Epperla, Narendranath, Loretta J. Nastoupil, Bruce Feinberg, John Galvin, Prathamesh Pathak, Theresa Amoloja, Danielle Gentile, and Kim Saverno. Real-world Use of Tafasitamab Preceding CD19-directed Chimeric Antigen Receptor T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma. BMC.

MLA (9th ed.) Citation

Epperla, Narendranath, et al. Real-world Use of Tafasitamab Preceding CD19-directed Chimeric Antigen Receptor T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma. BMC.